drugset / Trial / NCT04510207

A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above

NCT04510207 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a multicenter, randomized, double blind, parallel placebo controlled, phase 3 clinical trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines in healthy population 18 years old and above.

Timeline

Start
2020-07-16
Primary completion
2021-06-16
Completion
2021-12-31

Outcome

Met primary endpoint

paper vaccine efficacy, compared with alum-only, of 72.8% (95% CI, 58.1%-82.4%) for WIV04 and 78.1% (95% CI, 64.8%-86.3%) for HB02 (P < .001 for both). PMID 34037666 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject HB02 Vaccine 4 ug Intramuscular
Subject WIV04 Vaccine 5 ug Intramuscular

Indications